



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Sunday, November 22, 2009

## Cheil Jedang Corporation - CJ Pharma

[View the current Cheil Jedang Corporation - CJ Pharma Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/2650-Cheil+Jedang+Corporation++CJ+Pharma.html)

(<http://www.bioportfolio.com/biocorporate/2650-Cheil+Jedang+Corporation++CJ+Pharma.html>)

### Contact Details:

**212 Carnegie Center, Suite 302**  
**Princeton**  
**New Jersey**  
**08540**  
**United States of America**

Tel: 609 897 0780  
Fax: 609 897 0725  
Email: [ajhorman@cj.net](mailto:ajhorman@cj.net)

Since the establishment 42 years ago, CJ's biotechnology business has been giving efforts to develop products that fulfill everyone's desire for health by increasing product groups with its biotechnology represented by the mass fermentation technology and the wide variety of research in the pharmaceutical area.

CJ manufactured nucleic acids such as MSG (monosodium glutamate), IMP, GMP, and I&G starting with the production of condiments through the fermentation technology it developed for the first time in Korea in 1963. Also, it is playing a pivotal role in CJ's globalization through various activities such as the production of threonine and lysine, the growth promoter used with cattle feed in Indonesia, the place of the raw materials are produced, the exportation to European and American regions, and the establishment of plants in the place of raw material production. CJ is also giving much effort in strengthening R&D capacities such as it established a branch of Bio Research Center in Daejeon, the Mecca of bio-engineering and technology, to support technological development.

CJ started the pharmaceutical business in 1984, and it established a strong footing in the field as the company with strong research capabilities and potentials with the successful release of hepaccine, the vaccine for hepatitis-B. And now, it is growing into the world's leader in the pharmaceutical industry contributing to the healthy life of the patients in and out of the country with the continuous development of a variety of vaccines, cytokine, medicines for geriatric diseases, and antibiotics based on advanced bioengineering technology including the latest recombinant DNA technology.

The recent acquisition of Hanil Pharm reflected CJ's strong will to strengthen its capabilities in the pharmaceutical business with and gave CJ an opportunity to bring out the synergy in the sales and profit/loss areas and strengthen the overseas license network as Hanil Pharm has many original licenses for excellent foreign medicines such as Mevalotin, Bana, Herben, and Selbex.

CJ has laying the foundation for the development of the new products by making full use of the technological strength through the latest research facilities will continue to maintain its position as the leading company in the biotechnology and pharmaceutical areas in the growing global market through the know-how and the competitive strength with the price so that the customers can enjoy 'healthy' life and will lead the bio industry of the next generation by accelerating the development of environment-friendly biotechnical materials such as the microbiological products and biodegradable products.

## Press Releases on Cheil Jedang Corporation - CJ

### Pharma:

<a href="#">Centene Corporation to Present at Bank of America Merrill Lynch Credit Conference</a>	20th November, 2009	Centene Corporation	ST. LOUIS, Nov. 20 /PRNewswire-FirstCall/ -- Centene Corporation (NYSE: CNC) today announced that it will present at the Bank of America Merrill Lynch 2009 Credit Conference, to be held December 2-3,
<a href="#">Reportlinker Adds Power Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015</a>	20th November, 2009	Reportlinker	NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Power Wheelchair Market Shares, Strategies, and Forecasts, Worldwide,
<a href="#">Reportlinker Adds Medical Adhesives and Sealants - A US Market Review</a>	20th November, 2009	Reportlinker	NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Medical Adhesives and Sealants - A US Market Review <a href="http://www">http://www</a>
<a href="#">Reportlinker Adds Toothpaste - Global Market Trends</a>	20th November, 2009	Reportlinker	NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Toothpaste - Global Market Trends <a href="http://www.reportlinker.com/p0164389">http://www.reportlinker.com/p0164389</a>
<a href="#">Reportlinker Adds Global Self Monitoring Blood Glucose Market (SMBG): Increasing Adoption to Drive Growth</a>	20th November, 2009	Reportlinker	NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Global Self Monitoring Blood Glucose Market (SMBG): Increasing Adoption to

## BioNews Results for Cheil Jedang Corporation - CJ Pharma



- [Bioniche Pharma Acquires Duraclon \(clonidine hydrochloride injection\) and Methadone Hydrochloride Injection US](#)  
*Pharma Live: Nov 15 2009 7:05PM Matching: pharma*
- [Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain](#)  
*PRWeb via Yahoo!: Nov 15 2009 11:07PM Matching: pharma*
- [PharmiWeb Solutions - Making new friends](#)  
*PharmiWeb: Nov 15 2009 3:27AM Matching: pharma*
- [LEO Pharma Completes Peplin Acquisition](#)

- Pharma Live: Nov 15 2009 9:16AM Matching: pharma*
- [Testing Times For Mankind Pharma](#)  
*Businessworld India: Nov 15 2009 5:21PM Matching: pharma*
  - [Trade Talk: Fargo-based CSM partners with CRID PHARMA of France](#)  
*Fargo Forum: Nov 14 2009 9:16AM Matching: pharma*
  - [Leo Pharma completes merger pact with Peplin](#)  
*PharmaBiz: Nov 14 2009 9:54AM Matching: pharma*
  - [Bioniche Pharma Acquires Duraclon\(R\) \(clonidine hydrochloride injection\) and Methadone Hydrochloride Injection](#)  
*Entrepreneur.com: Nov 14 2009 2:31PM Matching: pharma*
  - [Astellas Pharma Inc. - Financial And Strategic Analysis Review - New Report Published](#)  
*OfficialSpin: Nov 14 2009 2:25PM Matching: pharma*
  - [Dainippon Sumitomo Pharma Co., Ltd. - Financial And Strategic Analysis Review - New Report Published](#)  
*OfficialSpin: Nov 14 2009 1:44PM Matching: pharma*
  - [BioAlliance Pharma Presents Results for Its New Oral Chemotherapy Nanoparticle Innovation](#)  
*Nanotechnology News: Nov 14 2009 7:47AM Matching: pharma*
  - [Trin Pharma wins German approval to initiate Phase I cancer trial](#)  
*Pharmacy Choice: Nov 14 2009 12:56AM Matching: pharma*
  - [Bioniche Pharma acquires Duraclon, Methadone HCl USP from Xanodyne](#)  
*PharmaBiz: Nov 14 2009 11:26AM Matching: pharma*
  - [Bioniche Pharma Acquires Duraclon\(R\) \(clonidine hydrochloride injection\) and Methadone Hydrochloride Injection](#)  
*Business Journal of Jacksonville: Nov 13 2009 1:40AM Matching: pharma*
  - [Bioniche Pharma Acquires Duraclon\(R\) \(clonidine hydrochloride injection\) and Methadone Hydrochloride Injection](#)  
*Pittsburgh Business Times: Nov 13 2009 12:03AM Matching: pharma*

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

